A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low Grade Serous Carcinoma of the Ovary or Peritoneum
Protocol: NRG – GY019 SCHEMA NRG-GY019 Please Note: Below is only a brief description of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038 to discuss the full eligibility requirements Eligibility: Patients must have newly diagnosed, Stage II-IV low-grade serous ovarian cancer (submission of pathology report(s) required). Ovarian cancer […]
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers
Protocol: ECOG – EAY191-N4 SCHEMA EAY191-E4 Please Note: Below is a partial list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038 to discuss the complete eligibility requirements. Thank you! Eligibility: Patients must be enrolled on the ComboMATCH Master Registration Trial EAY191 Patients must have RAS pathway mutations […]